MOTS-c, a mitochondrial-derived peptide, has garnered significant
attention for its role in metabolic regulation, cellular homeostasis, and muscle
maintenance. In chronic peritoneal dialysis patients, the risk of sarcopenia
is particularly high due to multiple contributing factors, including chronic
inflammation, oxidative stress, malnutrition, and prolonged exposure to
uraemic toxins. Sarcopenia, characterized by progressive loss of muscle mass
and function, significantly affects morbidity and mortality in dialysis patients.
Understanding the association between MOTS-c levels and sarcopenia risk
could provide valuable insights into potential therapeutic interventions and
early diagnostic markers.
Share this article
Journal of Nephrology & Therapeutics received 784 citations as per Google Scholar report
